NCT06680128View on ClinicalTrials.gov

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

June 26, 2026

Study Completion Date

March 19, 2028

Conditions
Japanese Encephalitis Virus Disease
Interventions
BIOLOGICAL

GBP560-A

"injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"

BIOLOGICAL

GBP560-B

"injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.~Low dose: 3μg Mid dose: 15μg High dose: 50μg"

BIOLOGICAL

IXIARO

injection volume of 0.5mL on V2(1day) and V5 (29day) in stage1 and stage2

BIOLOGICAL

IMOJEV

injection volume of 0.5mL on V5 (29day) in stage1 and stage2

BIOLOGICAL

Normal Saline (Placebo)

injection volume of 0.5mL on V2 (1day) in stage1 and stage2 (This is for IMOJEV placebo)

Trial Locations (3)

8011

NOT_YET_RECRUITING

New Zealand Clinical Research, Christchurch

Unknown

RECRUITING

Nucleus Network - Brisbane (Q Pharm), Brisbane

RECRUITING

Nucleus Network - Melbourne, Melbourne

All Listed Sponsors
lead

SK Bioscience Co., Ltd.

INDUSTRY